Ahead of Pending Studies on PGx-Based Plavix Administration, Is Quest/Scripps CYP2C19 Testing Alliance Premature? | GenomeWeb

By Turna Ray

WASHINGTON, DC — Quest Diagnostics' partnership with Scripps Health to offer CYP2C19 testing to stent procedure patients prior to treatment with the anti-platelet agent Plavix may be premature pending randomized controlled trials investigating the patient outcomes associated with testing, genomically guided Plavix dosing, and alternative treatments for CYP2C19 poor metabolizers, presenters at a conference on personalized medicine suggested this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.